We live in a nation led by people with strong opinions on every side of the aisle. I'm not even sure there is an aisle these days. But, there is always room for leaders to find common ground for the sake of the people they serve. I found some common ground on adding more jobs in the fastest growing part of Alabama's economy with Governor Ivey, Senator Katie Britt, and Congresswoman Terri Sewell. Birmingham is uniquely positioned to secure Alabama's economic future through #biotech. #alabama #nationalsecurity #cities #bipartisan #innovation #birminghamalabama #puttingpeoplefirst https://lnkd.in/gDqWwnfb
City of Birmingham Mayor's Office ’s Post
More Relevant Posts
-
🌱 Growing the UK Life Sciences 🔬 Dr Stella Peace, Executive Director of Healthy Living and Agriculture at Innovate UK, joins entrepreneurs, investors, and industry leaders at the 2024 Life Sciences Summit in Aberdeen. 🚀 In her keynote address, Stella highlights Innovate UK's commitment to inspiring, involving, and investing in innovation, particularly in bridging the gap between inception and commercialisation. Key pillars include: 💡 Power of Patience: Long-term investment in businesses, including £300M through the Biomedical Catalyst programme and the Bio-based Manufacturing Launchpad. 🏢 Power of Place: Support for innovation clusters across the UK, including the world-leading Cell and Gene Therapy Catapult in Edinburgh and Medicines Manufacturing Innovation Centre in Glasgow/Renfrewshire. 🤝 Power of Partnerships: Importance of local partnerships for accelerating regional growth, exemplified by initiatives like the Glasgow City Region Local Action Plan and MOU with Scottish Enterprise. 👥 Power of People: Securing the future pipeline of skills and talent in life sciences through programmes like Future Leaders Fellowships, Talent and Skills Connect, and No Limits. Life Sciences is critical for the UK's global impact, driven by innovation. Innovate UK is dedicated to advancing business innovation in life sciences, paving the way for longer, healthier lives. Our initiatives, including the Biomedical Catalyst programme, Transforming Medicines Manufacturing, and our today announced involvement in the Dame Barbara Windsor Dementia Mission, are tailored to bolster the life sciences industry, providing essential support for talent acquisition, growth, scaling, and more. Learn more about our work supporting Life Sciences businesses: https://ow.ly/AA6m50QXUwz #LifeSciences #Innovation #BusinessInnovation The Times
To view or add a comment, sign in
-
-
Biotech’s public policy pillars are crumbling. Without a meaningful change in public support, biomedical innovation will slow. Companies and investors must do more to convince policymakers the biopharma industry is a treasure worth nurturing. An editor's commentary by BioCentury Inc.'s Steve Usdin.
Biotech’s public policy pillars are crumbling
biocentury.com
To view or add a comment, sign in
-
Better healthcare starts here: The University of Ottawa’s new Advanced Medical Research Centre (AMRC) will play a crucial role in curbing Ottawa’s biotech brain drain. Ottawa has earned its global reputation as a vibrant city for medical research and innovation. But if it wants to keep its top researchers in the region and build a thriving biotech sector, more lab space and private investment will be needed, says Jean-Simon Diallo, who is founder and CEO of Virica Biotech Inc, scientist at the Ottawa Hospital Research Institute, and associate professor at the uOttawa | Faculté de médecine | Faculty of Medicine. At the Advanced Medical Research Centre (AMRC), researchers, health-care professionals and investors will team up to accelerate the discovery and commercialization of life-saving therapies. “The AMRC is a good example of the understanding that we need to get researchers to commercialize their intellectual property. But we also need to support them with the space and the equipment they need.” says Dane Bedward, CEO of NeuroBot Inc. and former senior vice president international for Genzyme Corporation. “There’s so much grey matter here, but so many inventions that have come out of Canada get gobbled up and taken outside Canada.” Read the article or watch the video to learn more about how the AMRC will provide huge opportunities for the next wave of Ottawa biotech researchers and entrepreneurs. - https://lnkd.in/g46-G9Au #uOttawa #uOttawaAMRC #BetterHealthcare #StartsHere #Ottawa #research #biotech
If you build it, they will stay: Ending Ottawa’s biotech brain drain | Research and innovation
uottawa.ca
To view or add a comment, sign in
-
It is fantastic to be back in Switzerland on my way from Zürch to Basel🇨🇭. This is Moa Persson and my second trip down here in a couple of months and the reason is that things are just happening here! The biotech sector seems to be exploding all over this region, with both mastodons of the medical world being here, but also a vast and flourishing ecosystem of smaller start-up's as well as exciting research being done at Universities. This is just the place for Symcel to be and from our meetings with academics and companies, we have a platform that is a perfect fit for this ecosystem! So much work is being done into the research of new #antimicrobials, #phages, and #celltherapy, that our solutions for complex in-vivo-like model systems as well as fast and sensitive detection of bacteria are a perfect match. This will not be our last trip down here! We are ready for so much more synergy with these amazing clusters of #biotechnologyindustry
To view or add a comment, sign in
-
-
Kudos to my #SVBHealthcare colleague Anton Xavier for penning this article on using government grants as a source of non-dilutive funding. Also, many thanks to Silicon Valley Bank for supporting our ability to produce insights that align with our mission of improving the probability of success for disruptive innovators. TLDR: This article delves into the realm of Biomedical Advanced Research and Development Authority (BARDA) and the Congressionally Directed Medical Research Program (CDMRP). https://lnkd.in/g38hkrB4
Non-dilutive capital for biotech startups | Silicon Valley Bank
svb.com
To view or add a comment, sign in
-
Wrapping up three dynamic days at Biotechnology Innovation Organization annual convention in San Diego, where we released Cure.’s inaugural biotech benchmark report, Ready, Set, Growth! Cure, an affiliate of Deerfield Management, conducted this highly anticipated assessment of the #biotech industry in partnership with the Deerfield Institute, a division of Deerfield Management. The survey included company #founders and #CEOs, #managing directors, #investors, #scientists, and more. Exciting insights from experts in the field revealed an overwhelming sense of #hope and #optimism across the biotech sector, with 79 percent of individuals betting on growth. Advances in #science and investment opportunities in areas like #neurology, #metabolicdisease, and #oncology, driven by cutting-edge technologies such as #cell and #genetherapies and #AI and #machinelearning are fueling this positivity. Despite progress in various key areas, the survey highlighted a significant lack of innovation and investment in #womenshealth. Nearly 65 percent of respondents expressed #support for more #investment in women’s health. This trend is encouraging, as increased attention and #government funds are now being directed towards women's health, paving the way for potential industry #growth and resurgence. The much-needed investment in #womenfounders and women's health could be the cornerstone for the biotech #comeback and expansion. While it’s hard to know if the trend lasts, nurturing the growth of women's health initiatives could be the #catalyst for the industry #turnaround we aspire to see. Thanks to Caroline D. Marion E. Glick Daniel Glass William Cheung Anna Howell Leah Rosenbaum Cedric Beckles Ben Green Leah Rosenbaum Paul Oestreicher Elizabeth Rose Hansen Rosie Zaloum Foster Dan Hoffman Lauren Ruotolo David Duncan for a terrific report and the ground team who brought everything to life including Caroline D. Susanna Ling Vilia Baumilas Alana Elliott and our new COO Charles Kim. Plus thanks to David Greenwald, Ph.D. Mary Stutts, MHA Jamie Metzl David Fajgenbaum, MD, MBA, MSc Grant W Mitchell, MD, MBA Brittany Connors, PMP Stephanie Fertig Matthew Portnoy Raheleh H. To read the report go to www.wewillcure.com Finishing up the morning with a panel on De-risking drug development with Wyatt Gotbetter Gotbetter Ned Wydysh Susan Billings, Ph.D. Dan Gold Abhiram Rao, PhD Parexel #BIO2024 #wewillcure
To view or add a comment, sign in
-
-
We're investing £1.6m through our Virtual Biotech programme to drive forward the development of a promising molecule which has potential to become a drug that slows or stops Parkinson’s. Partnering with US-based company Acurex Biosciences, we are supporting the final stages of testing and development of their molecule, CU-13001, in preparation for its progress into clinical trials. CU-13001 is a molecule that has shown exciting potential for protecting the brain cells that are lost in Parkinson’s in laboratory-based tests. It targets an enzyme called 15-lipoxygenase, which emerging research suggests may play an important role in the death of dopamine-producing cells in the condition. Arthur Roach, our Virtual Biotech Director, has said this is what we created the Virtual Biotech programme to do, to apply support from the Parkinson's community to accelerate bold new research to create potentially life-changing new therapies. For more information: https://prksn.uk/46CFnAU
To view or add a comment, sign in
-
-
"Advancing Novel Therapies for Neurodegeneration through an Innovative Model for Industry-Academia Collaborations: A Decade of the Eisai-UCL Experience" by Atkinson et al. is a case study on the industry-academia partnerships between Eisai-University College London (UCL) collaboration in the field of neurodegeneration research. Key takeaways include: 1. The Eisai and UCL partnership brought together complementary expertise from both parties. 2. Clearly defined needs and motivations enable collaboration design. 3. Joint committees and project teams drive decision-making and progress. 4. After 10 years, the collaboration was successful - 7 projects were initiated and 1 entered clinical trials. KSB understands the unique needs of academics and can provide state-of-the-art facilities and expertise to accelerate the translation of innovations from bench to bedside. Let's connect to discuss how we can contribute specialized CDMO capabilities to your academic partnerships and alliances. Article link: https://lnkd.in/gT33B3G2 #CDMO #drugdevelopment #partnership #biotech
To view or add a comment, sign in
-
-
📅 Next month, at the 2024 Life Sciences Summit, sector leaders from across the UK will unite in Aberdeen. 🤝 The summit, co-created and delivered by The Times and Opportunity North East Limited, will explore how one of the UK's most dynamic industries is tackling global health challenges through scientific creativity, commercial innovation and technological advancement and improving lives while delivering robust economic growth. Dr Martin Turner at BioIndustry Association (BIA) commented, "We've seen enormous change in the sector over the past ten years, we've seen growing levels of investment over 1,000% increase in investment. A lot of that is coming from American investors who are coming over here, recognising our science and that is driving more entrepreneurial behaviours, amongst academics as well, who are keen to spin out companies." Dr Poonam Malik, MBA, FRSE FRSB at Microplate Dx Limited said, "As companies that are working at the cutting edge of innovation, their products can solve multiple challenges, be it in antimicrobial resistance or cancer diagnosis or drug therapies. But they are looking for developing the pathway of collaborators to work alongside, but they are also looking for funders and investors." 🎞 Watch the video below 👇 ℹ To learn more about the summit and purchase your ticket, please follow the link in the comments below. #OpportunityNorthEast #lifesciences #Aberdeen
To view or add a comment, sign in
--
1moFIELD OF DREAMS